About: Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Sector: Healthcare
Industry: Biotechnology
Latest price: $26.98 (-6.38%)
NGNE NASDAQ Neurogene Inc
Neurogene Inc share price
NGNE price activity
Last Price
$26.980
Change (24hr)
-1.84 USD (6.38%)
Volume
52.51K
Volume (4w avg)
-
Open
$28.53
Day Range
$26.97 - $29.38
Previous Close
$28.82
Last Trade
30 Oct, 4:15 pm GMT+0
Delayed
30 Oct, 4:15 pm GMT+0
NGNE price performance
Delayed
30 Oct, 4:15 pm GMT+0
NGNE Market Signals